

Company Profile

Industry Sector: Audiological Medical Devices

Company Overview:

Mimosa Acoustics manufactures state-of-the-art auditory diagnostic systems for evaluating middle and inner-ear health.

Target Market(s):

Equipment for mandatory hearing screening
Hospitals, clinics, & birthing centers
Hearing specialists (audiologists, otolaryngologists)
Pediatricians & general practitioners
School & occupational safety screening programs
Audiological research & education institutions

Key Value Drivers

Technology*:

Mimosa Acoustics possesses the only FDA-approved device for wide band frequency analysis of the middle ear.

Competitive Advantage:

Mimosa Acoustics' patented diagnostic system is the only available method for obtaining diagnostic data about both the middle- and inner ear in a single test. Non-invasive testing takes only seconds and requires no patient response, meaning that it can be used on patients of all ages. Unlike widely-used tympanometry, Mimosa's test provides data across the broad speech frequency range and can be used for patients with ear tubes or painlessly on inflamed middle ears.

Plan & Strategy:

Mimosa has commenced an aggressive business development campaign in order to commercialize its technology.

Management

Leadership:

Pat Jeng, Ph.D., President
Jont Allen, Ph.D., Chief Technology Officer
Joseph Jeng, Director
Andrew C. Singer, Ph.D., Director

Closely held private company.

Pat Jeng & Jont Allen are recognized leaders within the audiological research community.

Product Development

FDA approved and commercially available since October 2006.

Single technology platform with multiple testing modules in any combination

- Middle Ear:
 - Middle Ear Power Analysis (MEPA)
- Inner Ear:
 - Distortion Product Otoacoustic Emissions (DPOAE)
 - Transient Evoked Otoacoustic Emissions (TEOAE)

